Related Experiment Video
Updated: Oct 26, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Inflammation, atrial fibrillation, and the potential role for colchicine therapy
Bibin Varghese1, David I Feldman1, Christopher Chew2
1Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract:
Increasing evidence suggests that the "NACHT-LRR and PYD domain-containing protein 3" (NLRP3) inflammasome plays an important role in atherosclerotic cardiovascular disease (ASCVD). Recent preclinical evidence has suggested that the NLRP3 inflammasome may play a prominent role in the pathogenesis of atrial fibrillation (AF). As such, the therapies that have shown efficacy in reducing ASCVD events may also prove beneficial in AF. In this article, we review the findings that implicate the NLRP3 inflammasome in the pathogenesis of AF, discuss existing evidence behind the use of anti-inflammatory agents for AF, and discuss the future role that colchicine and other anti-inflammatory agents may play in the prevention and treatment of AF.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Pericarditis III: Medical Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Myocarditis III: Medical Management
Rheumatic Heart Disease III: Medical Management
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...

